MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles

Theranostics

Volumn 4, Issue 8, 2014, Pages 845-857

  Sun, Yujin ^a,b   Kim, Hoe Suk ^a   Park, Jinho ^c   Li, Mulan ^a   Tian, Lianji ^a   Choi, YoonSeok ^a   Choi, Byung Ihn ^a   Jon, Sangyong ^c   Moon, Woo Kyung ^a  

^a Seoul National University Hospital   (South Korea)

^b YANBIAN UNIVERSITY   (China)

^c Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Aptides; Breast tumor initiating cells; Extra domain B of fibronectin; Magnetic resonance imaging.; Superparamagnetic iron oxide nanoparticles

Indexed keywords

FIBRONECTIN; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TUMOR MARKER; DEXTRAN; MAGNETITE NANOPARTICLE; NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CELL; BREAST TUMOR INITIATING CELL; CONTROLLED STUDY; COVALENT BOND; EXTRA DOMAIN B; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MCF 7 CELL LINE; MOLECULAR PROBE; MOUSE; NANOFABRICATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CROSS LINKING; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN TARGETING; TUMOR CELL; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CANCER STEM CELL; CELL DIFFERENTIATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; HYDRODYNAMICS; METABOLISM; NUDE MOUSE; PARTICLE SIZE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DEXTRANS; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDRODYNAMICS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASTIC STEM CELLS; PARTICLE SIZE; PROTEIN STRUCTURE, TERTIARY;

EID: 84903901410     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.8343     Document Type: Article

References (37)

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.
2. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
3. Liu H, Patel MR, Prescher JA, et al. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Aca Sci U S A. 2010;107:18115-20.
4. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555-67.
5. Potts JR, Campbell ID. Fibronectin structure and assembly. Curr Opin Cell Biol. 1994;6:648-55.
6. Birchler MT, Milisavlijevic D, Pfaltz M, et al. Expression of the extra domain B of fibronectin, a marker of angiogenesis, in head and neck tumors. Laryngoscope. 2003;113:1231-7.
7. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571-9.
8. Mhawech P, Dulguerov P, Assaly M, et al. EB-D fibronectin expression in squamous cell carcinoma of the head and neck. Oral Oncol. 2005;41:82-8.
9. Kosmehl H, Berndt A, Strassburger S, et al. Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer. 1999;81:1071-9.
10. Ricci E, Cavalot AL, Sanvito F, et al. Differential expression and topography of adhesion molecules in laryngeal and oropharyngeal carcinomas. Acta Otolaryngol. 2002;122:234-40.
11. Koukoulis GK, Howeedy AA, Korhonen M, et al. Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J Submicrosc Cytol Pathol. 1993;25:285-95.
12. Berndt A, Borsi L, Luo X, et al. Evidence of ED-B+ fibronectin synthesis in human tissues by non-radioactive RNA in situ hybridization. Investigations on carcinoma (oral squamous cell and breast carcinoma), chronic inflammation (rheumatoid synovitis) and fibromatosis (Morbus Dupuytren). Histochem Cell Biol. 1998;109:249-55.
13. Thakor AS, Gambhir SS. Nanooncology: The future of cancer diagnosis and therapy. CA Cancer J Clin. 2013;63:395-418.
14. Yu MK, Park J, Jon S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics. 2012;2:3-44.
15. Lee H, Yu MK, Park S, et al. Thermally cross-linked superparamagnetic iron oxide nanoparticles: synthesis and application as a dual imaging probe for cancer in vivo. J Am Chem Soc. 2007;129:12739-45.
16. Li M, Kim HS, Tian L, et al. Comparison of Two Ultrasmall Superparamagnetic Iron Oxides on Cytotoxicity and MR Imaging of Tumors. Theranostics. 2012;2:76-85.
17. Wang AZ, Bagalkot V, Vasilliou CC, et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 2008;3:1311-5.
18. Yu MK, Kim D, Lee IH, et al. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small. 2011;7:2241-9.
19. Yu MK, Park J, Jeong YY, et al. Integrin-targeting thermally cross-linked superparamagnetic iron oxide nanoparticles for combined cancer imaging and drug delivery. Nanotechnology. 2010;21:415102.
20. Kim S, Kim D, Jung HH, et al. Bio-inspired design and potential biomedical applications of a novel class of high-affinity peptides. Angew Chem Int Ed Engl. 2012;51:1890-4.
21. Park J, Kim S, Saw PE, et al. Fibronectin extra domain B-specific aptide conjugated nanoparticles for targeted cancer imaging. J Control Release. 2012;163:111-8.
22. Saw PE, Kim S, Lee IH, et al. Aptide-conjugated liposome targeting tumor- associated fibronectin for glioma therapy. J Mater Chem B. 2013;1:4723-6.
23. Neve RM, Chin K, Fridlyand J, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515-27.
24. Lee KM, Han W, Kim JB, et al. The CD49d+/high subpopulation from isolated human breast sarcoma spheres possesses tumor-initiating ability. Int J Oncol. 2012;40:665-72.
25. Choi Y, Kim HS, Cho KW, et al. Noninvasive identification of viable cell populations in docetaxel-treated breast tumors using ferritin-based magnetic resonance imaging. PloS One. 2013;8:e52931.
26. Hauger O, Delalande C, Deminiere C, et al. Nephrotoxic nephritis and obstructive nephropathy: evaluation with MR imaging enhanced with ultrasmall superparamagnetic iron oxide-preliminary findings in a rat model. Radiology. 2000;217:819-26.
27. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989;152:167-73.
28. Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15:R92.
29. Neri D, Carnemolla B, Nissim A, et al. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol. 1997;15:1271-5.
30. Birchler M, Neri G, Tarli L, et al. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. J Immunol Methods. 1999;231:239-48.
31. Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharm. 2009;157:220-33.
32. McCarthy JR, Bhaumik J, Karver MR, et al. Targeted nanoagents for the detection of cancers. Mol Oncol. 2010;4:511-28.
33. Benachour H, Seve A, Bastogne T, et al. Multifunctional Peptide-conjugated hybrid silica nanoparticles for photodynamic therapy and MRI. Theranostics. 2012;2:889-904.
34. Zheng Y, Liu Y, Jin H, et al. Scavenger receptor B1 is a potential biomarker of human nasopharyngeal carcinoma and its growth is inhibited by HDL-mimetic nanoparticles. Theranostics. 2013;3:477-86.
35. Goscin CP, Berman CG, Clark RA. Magnetic resonance imaging of the breast. Cancer Control. 2001;8:399-406.
36. Goodarzi N, Ghahremani MH, Amini M, Atyabi F, Ostad SN, Shabani Ravari N, et al. CD44-Targeted Docetaxel Conjugate for Cancer Cells and Cancer Stem-Like Cells: A Novel Hyaluronic Acid-Based Drug Delivery System. Chem Biol Drug Des. 2014; [Epub ahead of print].
37. McLaughlin R, Hylton N. MRI in breast cancer therapy monitoring. NMR Biomed. 2011;24:712-20.